Nektar Therapeutics Stock Is Trending Tuesday: What's Going On?
Strong Bullish
82.0
Shares of Nektar Therapeutics (NASDAQ:NKTR) are soaring Tuesday following a significant update regarding the company’s atopic dermatitis treatment.
Nektar Therapeutics stock is among today’s top performers. What’s behind NKTR gains?
Positive Dermatitis Treatment Data Boosts Stock
Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of rezpegaldesleukin, a novel regulatory T-cell (Treg) biologic, in patients with moderate-to-severe atopic dermatitis (AD).
The data revealed that 71% and 83% of patients maintained EASI-75 responses and 85% and 63% maintained vIGA-AD 0/1 responses with 24 µg/kg monthly and quarterly dosing, respectively. These promising results indicate a meaningful improvement in responses observed across key efficacy
Nektar Therapeutics stock is among today’s top performers. What’s behind NKTR gains?
Positive Dermatitis Treatment Data Boosts Stock
Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of rezpegaldesleukin, a novel regulatory T-cell (Treg) biologic, in patients with moderate-to-severe atopic dermatitis (AD).
The data revealed that 71% and 83% of patients maintained EASI-75 responses and 85% and 63% maintained vIGA-AD 0/1 responses with 24 µg/kg monthly and quarterly dosing, respectively. These promising results indicate a meaningful improvement in responses observed across key efficacy
Pulse AI Analysis
Pulse analysis not available yet. Click "Get Pulse" above.
This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.
